Source comparison
GHRP-2 Acetate vs Tesamorelin Which Better Comparison: Clinical Data Summary
Mechanism Ghrelin receptor (GHS-R1a) agonist → pulsatile GH release GHRH receptor agonist → selective somatotroph stimulation Tesamorelin offers receptor specificity; GHRP-2 provides broader pathway activation Cortisol Co-Release 20–40% transient elevation wit
This comparison does not assign a generated winner or score.
- Mechanism
- Ghrelin receptor (GHS-R1a) agonist → pulsatile GH release
- GHRH receptor agonist → selective somatotroph stimulation
- Tesamorelin offers receptor specificity; GHRP-2 provides broader pathway activation
- Cortisol Co-Release
- 20–40% transient elevation within 60–90 minutes
- Negligible elevation in clinical trials
- Tesamorelin avoids adrenal stress; GHRP-2 may complicate cortisol-sensitive research
- Visceral Fat Reduction
- General lipolysis across visceral + subcutaneous depots
- 15.2% VAT reduction at 26 weeks (COSMIX trial). Visceral-selective
- Tesamorelin demonstrates superior visceral-specific fat loss
- Lean Mass Accrual
- +2.1kg over 12 weeks in resistance-trained populations
- Minimal lean mass change in lipodystrophy trials
- GHRP-2 shows stronger anabolic signalling for muscle research
- Dosing Frequency
- 100–200mcg 2–3× daily (short half-life)
- 2mg once daily subcutaneously
- Tesamorelin's longer half-life simplifies dosing compliance
- Appetite Effect
- Dose-dependent hunger stimulation via ghrelin pathway
- None. GHRH pathway bypasses ghrelin-mediated feeding
- GHRP-2 complicates calorie-controlled metabolic studies
- FDA Approval
- None. Research-grade only
- Approved for HIV-associated lipodystrophy (2010)
- Tesamorelin has regulatory precedent; GHRP-2 remains investigational
- IGF-1 Elevation
- +40–60% above baseline at 200mcg 2× daily
- +30–50% above baseline at 2mg daily
- Both achieve therapeutic IGF-1 ranges; magnitude varies with protocol